222 related articles for article (PubMed ID: 17587338)
1. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Campbell RA; Sanchez E; Steinberg JA; Baritaki S; Gordon M; Wang C; Shalitin D; Chen H; Pang S; Bonavida B; Said J; Berenson JR
Br J Haematol; 2007 Aug; 138(4):467-78. PubMed ID: 17587338
[TBL] [Abstract][Full Text] [Related]
2. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.
Wen J; Feng Y; Huang W; Chen H; Liao B; Rice L; Preti HA; Kamble RT; Zu Y; Ballon DJ; Chang CC
Leuk Res; 2010 Jan; 34(1):85-92. PubMed ID: 19608275
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice.
Rousselot P; Larghero J; Labaume S; Poupon J; Chopin M; Dosquet C; Marolleau JP; Janin A; Brouet JC; Fermand JP
Eur J Haematol; 2004 Mar; 72(3):166-71. PubMed ID: 14962234
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
Canestraro M; Galimberti S; Savli H; Palumbo GA; Tibullo D; Nagy B; Guerrini F; Piaggi S; Cine N; Metelli MR; Petrini M
Cancer Genet Cytogenet; 2010 Jun; 199(2):110-20. PubMed ID: 20471514
[TBL] [Abstract][Full Text] [Related]
6. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
7. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
8. Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Jiang H; Ma Y; Chen X; Pan S; Sun B; Krissansen GW; Sun X
Cancer Sci; 2010 Apr; 101(4):975-83. PubMed ID: 20219070
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
Berenson JR; Boccia R; Siegel D; Bozdech M; Bessudo A; Stadtmauer E; Talisman Pomeroy J; Steis R; Flam M; Lutzky J; Jilani S; Volk J; Wong SF; Moss R; Patel R; Ferretti D; Russell K; Louie R; Yeh HS; Swift RA
Br J Haematol; 2006 Oct; 135(2):174-83. PubMed ID: 17010047
[TBL] [Abstract][Full Text] [Related]
10. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma.
Campbell RA; Manyak SJ; Yang HH; Sjak-Shie NN; Chen H; Gui D; Popoviciu L; Wang C; Gordon M; Pang S; Bonavida B; Said J; Berenson JR
Int J Oncol; 2006 Jun; 28(6):1409-17. PubMed ID: 16685443
[TBL] [Abstract][Full Text] [Related]
11. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
Sanchez E; Li M; Steinberg JA; Wang C; Shen J; Bonavida B; Li ZW; Chen H; Berenson JR
Br J Haematol; 2010 Feb; 148(4):569-81. PubMed ID: 19958357
[TBL] [Abstract][Full Text] [Related]
12. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
13. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
[TBL] [Abstract][Full Text] [Related]
14. Synergistic therapeutic effect of arsenic trioxide and radiotherapy in BALB/C nude mice bearing nasopharyngeal carcinoma xenografts.
Xie LX; Lin XH; Li DR; Chen JY; Hong CQ; Du CW
Exp Oncol; 2007 Mar; 29(1):45-8. PubMed ID: 17431388
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
Zhou L; Hou J; Fu W; Wang D; Yuan Z; Jiang H
Leuk Res; 2008 Nov; 32(11):1674-83. PubMed ID: 18485479
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
19. Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma.
Chen G; Wang Y; Huang H; Lin F; Wu D; Sun A; Chang H; Feng Y
Eur J Haematol; 2009 Mar; 82(3):176-83. PubMed ID: 19077051
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB.
Wei LH; Lai KP; Chen CA; Cheng CH; Huang YJ; Chou CH; Kuo ML; Hsieh CY
Oncogene; 2005 Jan; 24(3):390-8. PubMed ID: 15531921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
